Inventiva's Lanifibranor Achieves Dual Endpoints in NASH Trial, Analysts Project $2.6B Peak Sales
核心洞察
Inventiva's lanifibranor became the first drug to simultaneously achieve NASH (搜索) resolution and fibrosis improvement endpoints in a phase 2b trial, with 45% of patients resolving NASH at high dose versus 19% on placebo.
Jefferies (搜索) analysts raised peak sales projections to $2.6 billion annually following the positive trial results, which demonstrated significant improvements in both inflammation resolution and liver scarring reduction.
The company's phase 3 NATiV3 trial is fully enrolled with 1,009 patients in the registrational cohort, targeting an addressable U.S. F2/F3 MASH (搜索) population of approximately 375,000 patients.
Inventiva's lanifibranor has emerged as a potential blockbuster treatment for non-alcoholic steatohepatitis (NASH (搜索)) after becoming the first drug to simultaneously achieve dual regulatory endpoints in a clinical trial. The phase 2b NATIVE trial demonstrated significant improvements in both NASH resolution and fibrosis reduction, prompting analysts to project peak annual sales of $2.6 billion.
Phase 2b Trial Results Show Dual Efficacy
In the NATIVE trial, lanifibranor met twin endpoints relating to inflammation resolution and fibrosis despite only six months of treatment. At the high 1,200 mg dose, 45% of patients achieved NASH (搜索) resolution without worsening of fibrosis, compared with 33% at the low 800 mg dose and 19% in the placebo group.
The results were particularly compelling in the phase 3 target population of patients with F2-F3 disease, where liver scarring is present. In this subgroup, 44% of patients resolved symptoms at high dose and 34% at low dose, compared with only 9% on placebo.
For fibrosis improvement, 42% of patients on the high dose achieved at least one stage of fibrosis improvement without worsening of NASH (搜索), while 28% of patients on the low dose reached this goal.
Phase 3 Trial Fully Enrolled
Inventiva has fully enrolled its registrational phase 3 NATiV3 trial with 1,009 patients randomized 1:1:1, plus approximately 400 exploratory patients. The company is currently in data cleaning ahead of database lock, with top-line lanifibranor results expected in the second half of the year.
The phase 3 trial targets patients with F2/F3 MASH (搜索), representing an addressable U.S. population of approximately 375,000 patients. Unlike the phase 2 trial which included F1 patients, the phase 3 study excludes them. According to CEO Obenshain, removing F1 patients made effect sizes "the same to slightly better."
Positioning as GLP-1 Add-On Therapy
Lanifibranor is positioned as a pan-PPAR (搜索) oral candidate intended as an add-on to GLP-1 (搜索) medications. The phase 2b trial showed fibrosis and HbA1c benefits that management believes could be particularly valuable in F3 and diabetic patients.
The phase 3 trial includes more patients with diabetes, attributed to U.S.-based enrollment. Obenshain noted that efficacy in patients with diabetes was "the same to slightly better." Approximately 14% of phase 3 patients entered the trial on a stable GLP-1 (搜索) dose, which should be balanced across treatment arms.
Safety Profile and Market Opportunity
Safety issues have historically plagued dual pan-PPAR (搜索) agonists, but Jefferies (搜索) analysts characterized lanifibranor's safety profile as "broadly acceptable." Rates of peripheral edema were 6% to 8.5%, lower than the 14%-23% reported for pioglitazone, another PPAR drug. However, lanifibranor was associated with similar levels of weight gain as pioglitazone.
Management characterizes weight gain as a tolerability issue, with approximately 30% of patients experiencing 5% or greater weight gain. This can potentially be mitigated through SGLT2 (搜索) combination therapy.
Regulatory Timeline and Market Context
The company plans regulatory meetings in the last quarter of this year. Assuming standard phase 3 trial duration, the drug could potentially launch in 2025 if trials prove successful. Inventiva reports having cash runway through Q3 2027, assuming positive data and a €118 million financing tranche, positioning the company for potential self-launch.
Currently, no approved drugs exist for NASH (搜索), creating a significant market opportunity that pharmaceutical companies have targeted as potentially worth multiple billions of dollars. Intercept Pharmaceuticals (搜索)' obeticholic acid remains closest to market but has faced regulatory delays, with the FDA pushing back its decision timeline and requesting additional data.